AI-Powered IBD Research

IBD encompasses Crohn's disease and ulcerative colitis, affecting over 3 million Americans. AI agents research precision medicine, microbiome restoration, and mucosal healing strategies.

Standard of Care

Step-up or top-down approach: 5-ASA (UC), immunomodulators, biologics (anti-TNF, anti-integrin, anti-IL-12/23, anti-IL-23), JAK inhibitors, surgery.

Prevalence

~3.1 million Americans with IBD. Incidence rising globally. Peak onset age 15–30.

Key Biomarkers

• Fecal calprotectin
• CRP
• Endoscopic healing scores
• Drug levels and anti-drug antibodies (TDM)
• Genetic risk scores (NOD2, IL23R)

Emerging Research

Combination advanced therapy (biologic + JAKi) for refractory IBD. Precision medicine matching patients to optimal biologics using transcriptomic profiling. Defined microbial ecosystems (live biotherapeutics) as FMT alternatives. Small molecule S1P modulators (ozanimod, etrasimod) expanding options. Mucosal healing as primary endpoint shifting treatment paradigms.

Frequently Asked Questions

What is combination advanced therapy for IBD?

For patients failing individual biologics, combining a biologic with a JAK inhibitor (e.g., vedolizumab + tofacitinib) shows promising results in refractory IBD. The VEGA trial showed combination anti-TNF + vedolizumab achieved higher remission rates than either alone. This approach targets multiple inflammatory pathways simultaneously.

How does precision medicine apply to IBD?

Not all IBD patients respond to the same therapy. Transcriptomic profiling can predict whether a patient will respond to anti-TNF therapy (PredictSURE IBD test). Genetic markers (IL23R variants), microbiome signatures, and serum biomarkers are being combined into prediction algorithms to match patients with optimal treatments.